Studies have shown that Gleason score and levels of prostate specific antigen (PSA), a biomarker for prostate cancer [2,3,4], may be higher in AA prostate cancer (PCa) patients in comparison to their CA counterparts. This evidence concerns the gene KLK3 and prostate carcinoma.